News from company
- Oncology Venture: Successful DRP™ prediction of patients treated with 2X-121, the PARP inhibitor recently licensed from EisaiPosted on 1. August 2017 at 14:10
- Oncology Venture: Framgångsrik DRP™-förutsägelse av patienter behandlade med 2X-121, den nyligen licensierade PARP-hämmaren från EisaiPosted on 1. August 2017 at 14:10
- Oncology Venture: OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical companyPosted on 19. July 2017 at 9:00
- Oncology Venture: Oncology Venture och Eisai ingår exklusivt globalt licensavtal för den kliniska onkologiska läkemedelskandidaten PARP Inhibitor E7449/2X-121Posted on 7. July 2017 at 14:30
- Oncology Venture: Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121Posted on 7. July 2017 at 14:30
- Oncology Venture: LiPlaCis® Phase 2 now allowed for earlier inclusion & inclusion of patients with hard to treat breast cancerPosted on 6. July 2017 at 16:52
- Oncology Venture: Fas 2-studien med LiPlaCis® tillåts nu tidigare patientinkludering samt inkludering av patienter med svårbehandlad bröstcancerPosted on 6. July 2017 at 16:52
- Oncology Venture: Successful prediction of Cancer response to LiPlaCis® in Breast cancer and other tumors by OV's DRP™ - strong support for randomized Phase 2Posted on 27. June 2017 at 11:00
- Oncology Venture: Framgångsrik förutsägelse av respons med LiPlaCis® i bröstcancer och andra tumörtyper med OVs DRP - starkt stöd för randomiserad fas 2 i bröstcancerPosted on 27. June 2017 at 11:00
- Oncology Venture: Oncology Ventures spinout, 2X Oncology, får amerikanskt IND för 2X-111, ett liposomalt doxorubicin för bröst- och hjärncancerPosted on 8. June 2017 at 15:00
- Oncology Venture: OV's spinout - 2X Oncology Obtains US IND for 2X-111 a Liposomal Doxorubicin for Breast and Brain CancerPosted on 8. June 2017 at 15:00
- Oncology Venture: OV- The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP - Poster published at ASCOPosted on 5. June 2017 at 8:37
- Oncology Venture: Effekten av kemoterapi med epirubicin, ett av de mest använda läkemedlen mot bröstcancer, kan nu förutsägas av DRP - poster publicerad vid ASCOPosted on 5. June 2017 at 8:36
- Oncology Venture: Oncology Ventures andra läkemedelskandidat i klinik - första patienten med multipelt myelom i studie med APO010, ett immunonkologiskt läkemedelPosted on 31. May 2017 at 16:20
- Oncology Venture: OV`s second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drugPosted on 31. May 2017 at 16:20
- Oncology Venture: Oncology Venture - Successful US patent strategy - Irofulven Claims Accepted - English version of Swedish press release published Monday 29th May 2017Posted on 31. May 2017 at 12:25
- Oncology Venture: Framgångsrik amerikansk patentstrategi - ansökan om Irofulven accepteradPosted on 29. May 2017 at 16:30
- Oncology Venture: Interim Report 1 2017-01-01 - 2017-03-31Posted on 19. May 2017 at 11:05
- Oncology Venture: Delårsrapport 1 2017-01-01 - 2017-03-31Posted on 19. May 2017 at 11:05
- Oncology Venture: Effekten av kemoterapi med epirubicin, en av de mest använda läkemedlen mot bröstcancer, kan nu förutsägas av DRP-data publicerad vid ASCOPosted on 17. May 2017 at 23:00
- Oncology Venture: The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP - data published at ASCOPosted on 17. May 2017 at 23:00
- Oncology Venture: Corrected dates regarding last day of trading in BTAPosted on 16. May 2017 at 17:21
- Oncology Venture: Korrigerade datum avseende sista dag för handel med BTAPosted on 16. May 2017 at 17:21
- Oncology Venture: Sista dag för handel med BTAPosted on 16. May 2017 at 15:26
- Oncology Venture: Last day of trading in BTAPosted on 16. May 2017 at 15:26
- Oncology Venture: Kommuniké från årsstämma i Oncology Venture Sweden AB (publ)Posted on 8. May 2017 at 11:37
- Oncology Venture: Årsredovisning 2016Posted on 2. May 2017 at 13:36
- Oncology Venture: Kallelse till årsstämma i Oncology Venture Sweden AB (publ)Posted on 6. April 2017 at 12:44
- Oncology Venture: 2X Oncology Inc. utökar sin ledningsgrupp och utser George O. Elston till CEOPosted on 6. April 2017 at 11:46
- Oncology Venture: 2X Oncology Inc. expands U.S. Executive Team, names George O. Elston as CEOPosted on 6. April 2017 at 11:46
- Oncology Venture: Oncology Venture har rest cirka 33,7 MSEK genom företrädesemissionenPosted on 5. April 2017 at 17:14
- Oncology Venture: OncologyVenture has raised 33.7 MSEK in the rights issuePosted on 5. April 2017 at 17:14
- Oncology Venture: Oncology Venture Sweden AB announces approval of passportation of supplement to prospectusPosted on 30. March 2017 at 8:42
- Oncology Venture: Oncology Venture Sweden AB offentliggör godkännande av passportering av tilläggsprospektPosted on 30. March 2017 at 8:42
- Oncology Venture: Offentliggörande av tilläggsprospektPosted on 29. March 2017 at 15:53
- Oncology Venture: Publication of supplement to prospectusPosted on 29. March 2017 at 15:52
- Oncology Venture: Investors have committed to subscribe for a further approximately 5.1 MSEK in Oncology Ventures ongoing rights issuePosted on 29. March 2017 at 8:50
- Oncology Venture: Investerare har förbundit sig att teckna ytterligare cirka 5,1 MSEK i Oncology Ventures pågående företrädesemissionPosted on 29. March 2017 at 8:50
- Oncology Venture: Oncology Venture in-licenses 2-BBB's Phase 2 product 2B3-101 for 2X Oncology's pipelinePosted on 28. March 2017 at 14:30
- Oncology Venture: Oncology Venture inlicensierar 2BBB:s fas 2-produkt 2B3-101 till 2X Oncology Inc:s pipelinePosted on 28. March 2017 at 14:30
- Oncology Venture: Oncology Venture utvärderar onkologiläkemedel från Eisai Inc. för inlicensiering till 2X Oncology Inc.Posted on 24. March 2017 at 11:45
- Oncology Venture: Oncology Venture to evaluate Eisai oncology drug for in-license to 2X Oncology Inc.Posted on 24. March 2017 at 11:45
- Oncology Venture: Green light to Oncology Venture for DRP focused clinical APO010 study in Multiple MyelomaPosted on 21. March 2017 at 15:39
- Oncology Venture: Grönt ljus till Oncology Venture för DRP-fokuserad klinisk studie med APO010 i multipelt myelomPosted on 21. March 2017 at 15:39
- Oncology Venture: Oncology Venture Sweden AB announces start of subscription period of the rights issuePosted on 16. March 2017 at 8:45
- Oncology Venture: Idag inleds teckningstiden i Oncology Venture Sweden AB:s nyemissionPosted on 16. March 2017 at 8:45
- Oncology Venture: Oncology Venture Sweden AB announces approval on passportation of prospectusPosted on 15. March 2017 at 14:11
- Oncology Venture: Oncology Venture Sweden AB offentliggör godkännande av passportering av prospektPosted on 15. March 2017 at 14:11
- Oncology Venture: Offentliggörande av prospektPosted on 14. March 2017 at 15:01
- Oncology Venture: Publication of prospectusPosted on 14. March 2017 at 15:01
- Oncology Venture: Nytt datum för årsstämmaPosted on 14. March 2017 at 9:03
- Oncology Venture: New date for Annual General MeetingPosted on 14. March 2017 at 9:03
- Oncology Venture: Oncology Venture receives 1,000,000 SEK through exercise of warrants of series 2019Posted on 8. March 2017 at 16:50
- Oncology Venture: Oncology Venture tillförs cirka 1 000 000 SEK genom nyttjande av teckningsoptioner av serie 2019Posted on 8. March 2017 at 16:50
- Oncology Venture: Communiqué from the Extraordinary Shareholders' Meeting of Oncology Venture Sweden AB (publ)Posted on 1. March 2017 at 11:02
- Oncology Venture: Kommuniké från extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 1. March 2017 at 11:02
- Oncology Venture: Optimized LiPlaCis® allows for easier storage and transportationPosted on 21. February 2017 at 13:45
- Oncology Venture: Optimerad LiPlaCis® möjliggör enklare förvaring och transportPosted on 21. February 2017 at 13:45
- Oncology Venture: Invitation to Attend the Extraordinary General Meeting of Shareholders of Oncology Venture Sweden AB (publ)Posted on 13. February 2017 at 8:45
- Oncology Venture: Kallelse till extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 13. February 2017 at 8:45
- Oncology Venture: Decision on rights issue subject to approval at Extraordinary General MeetingPosted on 13. February 2017 at 8:30
- Oncology Venture: Beslut om företrädesemission villkorat av godkännande vid extra bolagsstämmaPosted on 13. February 2017 at 8:30
- Oncology Venture: Bokslutskommuniké 2016-01-01 - 2016-12-31Posted on 8. February 2017 at 9:10
- Oncology Venture: Status and Up-date on Oncology Venture & SPV pipelinesPosted on 31. January 2017 at 15:58
- Oncology Venture: Statusuppdatering avseende Oncology Ventures och SPV:ernas pipelinePosted on 31. January 2017 at 15:58
- Oncology Venture: DRP förutspår framgångsrikt effekten av 4 bröstcancerläkemedel för Personalized MedicinePosted on 24. January 2017 at 11:30
- Oncology Venture: DRP successfully predicts effect of 4 Breast Cancer drugs for Personalized MedicinePosted on 24. January 2017 at 11:30
- Oncology Venture: EUROSTARS funding of app. 1.9 mEUR (18 mSEK) granted to OV's LiPlaCis Phase 2 projectPosted on 19. January 2017 at 14:30
- Oncology Venture: EUROSTARS-finansiering om cirka 1,9 MEUR (18 MSEK) har beviljats för OV:s LiPlaCis i fas 2Posted on 19. January 2017 at 14:30
- Oncology Venture: Communiqué from the Extraordinary Shareholders' Meeting of Oncology Venture Sweden AB (publ)Posted on 17. January 2017 at 11:43
- Oncology Venture: Kommuniké från extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 17. January 2017 at 11:43
- Oncology Venture: DRP™ för Oncology Ventures ledande produkt LiPlaCis® har registrerats för CE-märkning i EUPosted on 9. January 2017 at 9:00
- Oncology Venture: DRP™ for Oncology Ventures lead product LiPlaCis® registered for CE-marking in EUPosted on 9. January 2017 at 9:00
- Oncology Venture: Marie Foegh, MD, DrSc, has accepted the position as CEO of 2X Oncology Inc. an OV spinoutPosted on 3. January 2017 at 15:16
- Oncology Venture: Marie Foegh, MD, DrSc, har accepterat positionen som VD för 2X Oncology Inc., en avknoppning från Oncology VenturePosted on 3. January 2017 at 15:16
- Oncology Venture: Notice to extraordinary shareholders' meeting in Oncology Venture Sweden AB (publ)Posted on 30. December 2016 at 9:44
- Oncology Venture: Kallelse till extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 30. December 2016 at 9:44
- Oncology Venture: OV secures seed financing for two SPVs, DRP exclusivity and share agreements with MPIPosted on 30. December 2016 at 9:00
- Oncology Venture: OV säkrar seedfinansiering för två SPVn, DRP exklusivitet och aktieavtal med MPIPosted on 30. December 2016 at 9:00
- Oncology Venture: Corrected dates regarding last day of trading in BTAPosted on 9. December 2016 at 16:00
- Oncology Venture: Korrigerade datum avseende sista dag för handel med BTAPosted on 9. December 2016 at 16:00
- Oncology Venture: Last day of trading in BTAPosted on 9. December 2016 at 9:34
- Oncology Venture: Sista dag för handel med BTAPosted on 9. December 2016 at 9:34
- Oncology Venture: Oncology Ventures ledande produkt LiPlaCis är nu i fas 2Posted on 21. November 2016 at 16:33
- Oncology Venture: Oncology Ventures lead product LiPlaCis is now in phase 2Posted on 21. November 2016 at 16:31
- Oncology Venture: Oncology Ventures' new rights issue oversubscribedPosted on 16. November 2016 at 16:21
- Oncology Venture: Oncology Ventures företrädesemission övertecknadPosted on 16. November 2016 at 16:21
- Oncology Venture: Idag inleds teckningstiden i Oncology Venture Sweden AB:s nyemissionPosted on 27. October 2016 at 8:40
- Oncology Venture: Offentliggörande av memorandumPosted on 26. October 2016 at 9:00
- Oncology Venture: Delårsrapport 2016-01-01 - 2016-09-30Posted on 19. October 2016 at 11:11
- Oncology Venture: Kommuniké från extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 11. October 2016 at 15:42
- Oncology Venture: Communiqué from the Extraordinary General Meeting of Oncology Venture Sweden AB (publ)Posted on 11. October 2016 at 15:42
- Oncology Venture: Poster avseende immunonkologiska APO010s känslighet i multipelt myelom presenteras vid European Society of Medical Oncology (ESMO)Posted on 10. October 2016 at 9:00
- Oncology Venture: Poster on Immuno Oncology APO010 sensitivity in Multiple Myeloma presented at European Society of Medical Oncology (ESMO)Posted on 10. October 2016 at 9:00
- Oncology Venture: Poster on Successful DRP prediction of cisplatin and vinorelbine in lung cancer presented at European Society of Medical Oncology (ESMO)Posted on 8. October 2016 at 9:00
- Oncology Venture: Poster avseende framgångsrik DRP-förutsägelse av cisplatin och vinorelbin i lungcancer presenteras vid European Society of Medical Oncology (ESMO)Posted on 8. October 2016 at 9:00
- Oncology Venture: Samtliga fyra danska center har påbörjat screening av patienter med multipelt myelom i OVs APO010-studiePosted on 7. October 2016 at 17:31
- Oncology Venture: All four Danish centers have started screening Multiple Myeloma patients for OV's APO010 StudyPosted on 7. October 2016 at 17:31
- Oncology Venture: Abstract för European Society of Medical Oncology (ESMO) tillgängliga online på onsdag den 28 september, 2016 kl. 12.00 (CET)Posted on 28. September 2016 at 12:00
- Oncology Venture: Abstracts for European Society of Medical Oncology (ESMO) available online on Wednesday, 28th September 2016 12.00 (CET)Posted on 28. September 2016 at 12:00
- Oncology Venture: Oncology Venture - Patent avseende Drug Response Predictor-teknologin beviljat i KinaPosted on 27. September 2016 at 17:46
- Oncology Venture: Oncology Venture - Patent on Drug Response Predictor technology granted in ChinaPosted on 27. September 2016 at 17:42
- Oncology Venture: Invitation to Attend the Extraordinary General Meeting of Shareholders of Oncology Venture Sweden AB (publ)Posted on 23. September 2016 at 8:45
- Oncology Venture: Kallelse till extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 23. September 2016 at 8:45
- Oncology Venture: Beslut om företrädesemission villkorat av godkännande vid extra bolagsstämmaPosted on 22. September 2016 at 9:09
- Oncology Venture: Decision on rights issue subject to approval at Extraordinary General MeetingPosted on 22. September 2016 at 9:09
- Oncology Venture: Statusuppdatering och planerad företrädesemissionPosted on 20. September 2016 at 9:45
- Oncology Venture: Status up-date and planned rights issuePosted on 20. September 2016 at 9:44
- Oncology Venture: Oncology Venture enters development deal with Cadila Pharmaceuticals on LiPlaCis® and its Drug Response PredictorPosted on 20. September 2016 at 9:43
- Oncology Venture: Oncology Venture tecknar utvecklingsavtal med Cadila Pharmaceuticals Ltd. avseende LiPlaCis® och dess Drug Response PredictorPosted on 20. September 2016 at 9:43
- Oncology Venture: Oncology Ventures in-licensed DRP tool for drug development to be studied by MPI as tool for Personalized Medicine in breast cancerPosted on 14. September 2016 at 12:21
- Oncology Venture: Oncology Ventures inlicensierade DRP-verktyg för läkemedels-utveckling ska studeras av MPI för Personalized Medicine i bröstcancerPosted on 14. September 2016 at 12:21
- Oncology Venture: Oncology Venture inkorporerar 2X Oncology Inc., ett företag i USA inriktat mot cancer hos kvinnorPosted on 9. September 2016 at 15:23
- Oncology Venture: Oncology Venture incorporates 2X Oncology Inc., a Women's Cancer Company in the USPosted on 9. September 2016 at 15:23
- Oncology Venture: Båda de danska centrerna i screeningstudien för Irofulven avseende patienter med prostatacancer är nu öppnaPosted on 8. September 2016 at 16:36
- Oncology Venture: Both Danish sites now open in the Screening Study of prostate cancer patients for OV's IrofulvenPosted on 8. September 2016 at 16:36
- Oncology Venture: Half-Year Report, 2016-01-01 - 2016-06-30Posted on 25. August 2016 at 16:09
- Oncology Venture: Halvårsrapport, 2016-01-01 - 2016-06-30Posted on 25. August 2016 at 16:09
- Oncology Venture: Uppdatering från Oncology VenturePosted on 25. August 2016 at 15:04
- Oncology Venture: Oncology Venture Up-datePosted on 25. August 2016 at 15:04
- Oncology Venture: OV LiPlaCis - Första DRP-positiva bröstpatienten har visat reduktion av tumörPosted on 23. August 2016 at 9:18
- Oncology Venture: OV LiPlaCis™ - First DRP-positive Breast Cancer Patient obtained reduction of tumorPosted on 23. August 2016 at 9:18
- Oncology Venture: Additional two centers started screening of Multiple Myeloma patients in OV's APO010 StudyPosted on 19. August 2016 at 16:50
- Oncology Venture: Ytterligare två center har inkluderats och påbörjat screening av patienter med multipelt myelom i OVs APO010-studiePosted on 19. August 2016 at 16:50
- Oncology Venture: Cisplatin and APO010 abstracts selected by ESMO's Scientific Committee for poster presentation on its annual congressPosted on 8. August 2016 at 13:55
- Oncology Venture: OV secures new Drug Response Predictor for potential new drug candidatePosted on 5. July 2016 at 14:19
- Oncology Venture: OV säkrar DRP för ny läkemedelskandidatPosted on 5. July 2016 at 14:19
- Oncology Venture: Screeningstudie av prostatacancerpatienter till Oncology Ventures Irofulven har godkänts av etiska kommittéer i Sverige och DanmarkPosted on 21. June 2016 at 8:45
- Oncology Venture: Screening Study of prostate cancer patients for OV's Irofulven approved by Ethics Committees in Sweden and DenmarkPosted on 21. June 2016 at 8:45
- Oncology Venture: Oncology Ventures immunonkologiläkemedel APO010 mot Multipelt Myelom erhåller EUROSTARS-bidrag från Norge till ett totalt värde av 12,7 MNOKPosted on 17. June 2016 at 10:56
- Oncology Venture: Oncology Venture's immuno-oncology drug APO010 for Multiple Myeloma receives EUROSTARS grant of a total value of 12,7 mNOK from NorwayPosted on 17. June 2016 at 10:56
- Oncology Venture: Last day of trading in BTAPosted on 16. June 2016 at 14:01
- Oncology Venture: Sista dag för handel med BTAPosted on 16. June 2016 at 14:01
- Oncology Venture: Oncology Ventures new rights issue oversubscribedPosted on 1. June 2016 at 13:37
- Oncology Venture: Oncology Ventures företrädesemission övertecknadPosted on 1. June 2016 at 13:36
- Oncology Venture: OV LiPlaCis™: första bröstcancerpatienten behandlad i första prospektiv studiePosted on 31. May 2016 at 15:28
- Oncology Venture: OV LiPlaCis™ - First Screened Breast Cancer Patient Dosed in First Prospective StudyPosted on 31. May 2016 at 15:28
- Oncology Venture: Offentliggörande av tilläggsprospektPosted on 19. May 2016 at 14:14
- Oncology Venture: Data publicerade i PLOS ONE om Oncology Ventures DRP för identifiering av patienter som svarar på behandling med 5-FUPosted on 12. May 2016 at 20:00
- Oncology Venture: Oncology Ventures DRP for identification of patients who benefit from 5-FU treatment - data published in PLOS ONEPosted on 12. May 2016 at 20:00
- Oncology Venture: Subscription Period for Rights Issue in Oncology Venture Sweden AB Begins TodayPosted on 12. May 2016 at 8:55
- Oncology Venture: Idag inleds teckningstiden i Oncology Venture Sweden AB:s nyemissionPosted on 12. May 2016 at 8:55
- Oncology Venture: Offentliggörande av prospekt och information om investerarträffarPosted on 11. May 2016 at 12:26
- Oncology Venture: Delårsrapport 2016-01-01 - 2016-03-31Posted on 3. May 2016 at 15:43
- Oncology Venture: Nytt datum för publicering av Q1-rapportPosted on 3. May 2016 at 13:56
- Oncology Venture: OV erhåller tre DRP:er för potentiella nya läkemedelskandidaterPosted on 27. April 2016 at 15:06
- Oncology Venture: OV acquires three DRP's for potential new drug candidatesPosted on 27. April 2016 at 15:06
- Oncology Venture: Kommuniké från extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 26. April 2016 at 15:27
- Oncology Venture: Positive data from Oncology Venture's Lead Product LiPlaCisPosted on 26. April 2016 at 13:35
- Oncology Venture: Positiva resultat för OV:s ledande produkt LiPlaCisPosted on 26. April 2016 at 13:35
- Oncology Venture: Kommuniké från årsstämma i Oncology Venture Sweden AB (publ)Posted on 26. April 2016 at 12:45
- Oncology Venture: Kallelse till extra bolagsstämma i Oncology Venture Sweden AB (publ)Posted on 8. April 2016 at 9:28
- Oncology Venture: Beslut om företrädesemission villkorat av godkännande vid extra bolagsstämmaPosted on 8. April 2016 at 9:08
- Oncology Venture: Årsredovisning för 2015 tillgängligPosted on 6. April 2016 at 10:58
- Oncology Venture: Kallelse till årsstämma i Oncology Venture Sweden AB (publ)Posted on 24. March 2016 at 12:55
- Oncology Venture: First Patient Included in OV's APO010 Screening StudyPosted on 10. March 2016 at 16:40
- Oncology Venture: Första patienten inkluderad i OV:s screening för APO010Posted on 10. March 2016 at 16:40
- Oncology Venture: Oncology Venture presenterar LiPlaCis vid AACR i New OrleansPosted on 4. March 2016 at 16:22
- Oncology Venture: Oncology Venture presents LiPlaCis on AACR in New OrleansPosted on 4. March 2016 at 16:22
- Oncology Venture: APO010 screening protocol approvedPosted on 3. March 2016 at 10:04
- Oncology Venture: Oncology Ventures screeningprotokoll för APO010 godkäntPosted on 3. March 2016 at 10:04
- Oncology Venture: Year-end ReportPosted on 19. February 2016 at 15:51
- Oncology Venture: BokslutskommunikéPosted on 19. February 2016 at 15:51
- Oncology Venture: OV inlicensierar LiPlaCis™ som sin tredje läkemedelskandidatPosted on 19. February 2016 at 14:45
- Oncology Venture: OV in-licensed LiPlaCis™ as third drug in OV pipelinePosted on 19. February 2016 at 14:45
- Oncology Venture: Positive results with DRP™ tool in gastroesophageal cancerPosted on 17. February 2016 at 20:01
- Oncology Venture: Positiva resultat för DRP™ vid esofaguscancerPosted on 17. February 2016 at 20:01
- Oncology Venture: Nytt datum för publicering av bokslutskommunikéPosted on 17. February 2016 at 11:23
- Oncology Venture: OV in-licensierade teknologin DRP™ erhåller patentPosted on 28. January 2016 at 8:22
- Oncology Venture: Oncology Venture har lämnat in screeningprotokoll för APO010Posted on 18. December 2015 at 13:07
- Oncology Venture: Oncology Venture has submitted the APO010 screening protocolPosted on 18. December 2015 at 13:07
- Oncology Venture: Interim Report 2015-01-01 - 2015-09-30Posted on 20. November 2015 at 9:16
- Oncology Venture: Delårsrapport 2015-01-01 - 2015-09-30Posted on 20. November 2015 at 9:16
- Oncology Venture: Oncology Venture Up-datePosted on 9. November 2015 at 17:33
- Oncology Venture: Uppdatering från Oncology VenturePosted on 9. November 2015 at 17:32
- Oncology Venture: DRP™ enables Irofulven clinical trial in prostate cancerPosted on 8. November 2015 at 18:30
- Oncology Venture: DRP™ möjliggör klinisk studie av IrofulvenPosted on 8. November 2015 at 18:30
- Oncology Venture: Presentation of use of DRP™ in Top1 on congress in BostonPosted on 6. November 2015 at 18:15
- Oncology Venture: Presentation av användande av DRP™ Top1 vid kongress i BostonPosted on 6. November 2015 at 18:15
- Oncology Venture: OV has incorporated its APO010 DRP™ in its clinical programPosted on 30. September 2015 at 9:00
- Oncology Venture: OV införlivar APO010 DRP™ i sitt kliniska programPosted on 30. September 2015 at 9:00
- Oncology Venture: Halvårsrapport 2015-01-01 - 2015-06-30Posted on 20. August 2015 at 13:00
- Oncology Venture: Optionsprogram i Oncology Venture Sweden ABPosted on 21. July 2015 at 9:01
- Oncology Venture: Option programmes in Oncology Venture Sweden ABPosted on 21. July 2015 at 9:01
- Oncology Venture: The new issue prior to listing on AktieTorget heavily oversubscribedPosted on 29. June 2015 at 16:03
- Oncology Venture: Nyemissionen inför notering på AktieTorget kraftigt övertecknadPosted on 29. June 2015 at 16:03
- Oncology Venture: Idag inleds teckningstiden – nyemission i Oncology Venture Sweden AB inför notering på AktieTorgetPosted on 5. June 2015 at 9:10
Media releases a.o.
2017 Juni 8
Oncology Ventures spinout, 2X Oncology, får amerikanskt IND för 2X-111, ett liposomalt doxorubicin för bröst- och hjärncancer
2017 June 8
OV’s spinout – 2X Oncology Obtains US IND for 2X-111 a Liposomal Doxorubicin for Breast and Brain Cancer
2017 Juni 6
Effekten av kemoterapi med epirubicin, ett av de mest använda läkemedlen mot bröstcancer, kan nu förutsägas av DRP – poster publicerad vid ASCO
2017 June 6
OV- The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP – Poster published at ASCO
2017 Maj 31
Oncology Ventures andra läkemedelskandidat i klinik – första patienten med multipelt myelom i studie med APO010, ett immunonkologiskt läkemedel
2017 May 31
OV`s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug
2017 Maj 29
Framgångsrik amerikansk patentstrategi – ansökan om Irofulven accepterad
2017 May 29
Oncology Venture – Successful US patent strategy – Irofulven Claims Accepted – English version of Swedish press release published Monday 29th May 2017
2017 Maj 19
Delårsrapport 1 2017-01-01 – 2017-03-31
2017 May 19
Interim Report 1 2017-01-01 – 2017-03-31
2017 Maj 17
Effekten av kemoterapi med epirubicin, en av de mest använda läkemedlen mot bröstcancer, kan nu förutsägas av DRP-data publicerad vid ASCO
2017 May 17
The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP – data published at ASCO
2017 Maj 16
Marknadsmeddelande 134/17 – Sista dag för handel med BTA i Oncology Venture Sweden AB – korrigerad version
2017 Maj 16
Korrigerade datum avseende sista dag för handel med BTA
2017 May 16
Corrected dates regarding last day of trading in BTA
2017 Maj 8
Kommuniké från årsstämma i Oncology Venture Sweden AB (publ)
2017 Maj 2
Årsredovisning 2016
2017 April 6
Kallelse till årsstämma i Oncology Venture Sweden AB (publ)
2017 April 6
2X Oncology Inc. utökar sin ledningsgrupp och utser George O. Elston till CEO
2017 April 6
2X Oncology Inc. expands U.S. Executive Team, names George O. Elston as CEO
2017 April 5
Oncology Venture har rest cirka 33,7 MSEK genom företrädesemissionen
2017 April 5
OncologyVenture has raised 33.7 MSEK in the rights issue
2017 Mars 30
Oncology Venture Sweden AB offentliggör godkännande av passportering av tilläggsprospekt
2017 March 30
Oncology Venture Sweden AB announces approval of passportation of supplement to prospectus
2017 Mars 29
Offentliggörande av tilläggsprospekt
2017 March 29
Publication of supplement to prospectus
2017 Mars 29
Investerare har förbundit sig att teckna ytterligare cirka 5,1 MSEK i Oncology Ventures pågående företrädesemission
2017 March 29
Investors have committed to subscribe for a further approximately 5.1 MSEK in Oncology Ventures ongoing rights issue
2017 Mars 28
Oncology Venture inlicensierar 2BBB:s fas 2-produkt 2B3-101 till 2X Oncology Inc:s pipeline
2017 March 28
Oncology Venture in-licenses 2-BBB’s Phase 2 product 2B3-101 for 2X Oncology’s pipeline
2017 Mars 24
Oncology Venture utvärderar onkologiläkemedel från Eisai Inc. för inlicensiering till 2X Oncology Inc.
2017 March 24
Oncology Venture to evaluate Eisai oncology drug for in-license to 2X Oncology Inc.
2017 Mars 21
Grönt ljus till Oncology Venture för DRP-fokuserad klinisk studie med APO010 i multipelt myelom
2017 March 21
Green light to Oncology Venture for DRP focused clinical APO010 study in Multiple Myeloma
2017 Mars 16
Idag inleds teckningstiden i Oncology Venture Sweden AB:s nyemission
2017 March 16
Oncology Venture Sweden AB announces start of subscription period of the rights issue
2017 Mars 15
Oncology Venture Sweden AB offentliggör godkännande av passportering av prospekt
2017 March 15
Oncology Venture Sweden AB announces approval on passportation of prospectus
2017 Mars 14
Offentliggörande av prospekt
2017 March 14
Publication of prospectus
2017 Mars 14
Nytt datum för årsstämma
2017 March 14
New date for Annual General Meeting
2015 Juli 22
Första dag för handel i Oncology Venture Sweden AB:s aktier på AktieTorget
2015 Juli 22
First day of trading for Oncology Venture Sweden AB at the AktieTorget
2015 March 16
Massachusetts Life Sciences Center and international partners announce new grants through International Collaborative Industry Program
2015 March 06
Oncology Venture, Lantern Pharma secure ICIP grant for Irofulven in treating metastatic prostate cancer
Pharmaceutical Business Review – PBR:
2015 March 04
MPI’s spinout Oncology Venture and Lantern Pharma receive grant to advance Irofulven for metastatic prostate cancer
MedWatch: Dansk firma får penge til udvikling af kræftmiddel (Danish only)
2015 February 20
MedWatch: Dansk spinout får kapitalrejsning (Danish only)
2015 February 19
MPI’s spinout Oncology Venture receives funding